Cynosure Inc (CYNO) 10-Q Quarterly Report May 2016


Timothy Baker		Scott Solomon
President, Chief Operating Officer		Senior Vice President
and Chief Financial Officer		Sharon Merrill Associates
Cynosure, Inc.		(617) 542-5300
(978) 256-4200		CYNO@investorrelations.com
tbaker@cynosure.com

Cynosure Announces Record First-Quarter 2016 Results;

Revenues Increase 26% from Prior Year to $94.7 Million

First-Quarter 2016 Highlights:

•

North America product revenue of $55.2 million, up 76 percent year-over-year

•

Non-GAAP earnings of $0.19 per diluted share; GAAP earnings of $0.12 per diluted share

•

Non-GAAP margin up 90 bps to 60.1%; GAAP gross margin improves 140 bps to 58.5%

•

Full U.S. rollout of SculpSure^® platform for non-invasive fat reduction helps pace strong double-digit revenue growth in North America

•

Cash and investments of $178.2 million at March 31, 2016

Westford, MA – April 26, 2016 – Cynosure, Inc. (Nasdaq: CYNO), which designs, manufactures and markets medical devices for aesthetic procedures and precision surgical applications worldwide, today reported financial results for the three months ended March 31, 2016.

“Sustained momentum in North America, in part reflecting the full U.S. launch of SculpSure, helped generate solid first-quarter results for Cynosure, as our domestic business posted year-over-year top-line growth for the 22^nd consecutive quarter,” said Chief Executive Officer Michael Davin. “Higher revenue and favorable product mix drove increased margins and profitability, even as we accelerated our sales and marketing investments during the quarter to coincide with the rollout of SculpSure across all of our U.S. direct sales territories. We are extremely pleased with the progress of the launch and the response SculpSure is receiving from physicians and patients.”

The following information was filed by Cynosure Inc (CYNO) on Tuesday, April 26, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

Please wait while we load the requested 10-Q report or click the link below:

https://last10k.com/sec-filings/report/885306/000119312516585840/d146934d10q.htm

View differences made from one quarter to another to evaluate Cynosure Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Cynosure Inc.

Continue

Assess how Cynosure Inc's management team is paid from their Annual Proxy

Cynosure Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2016 10-K Annual Report includes:

Voting Procedures
Board Members
Executive Team
Salaries, Bonuses, Perks
Peers / Competitors

Continue

Financial Statements, Disclosures and Schedules

Inside this 10-Q Quarterly Report

Material Contracts, Statements, Certifications & more

Cynosure Inc provided additional information to their SEC Filing as exhibits

Exhibit 10.4: Material Contract

Exhibit 31.1: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 31.2: Rule 13A-14(A)/15D-14(A) Certification

Exhibit 32.1: Section 1350 Certification

Exhibit 32.2: Section 1350 Certification

Ticker: CYNO
CIK: 885306
Form Type: 10-Q Quarterly Report
Accession Number: 0001193125-16-585840
Submitted to the SEC: Tue May 10 2016 5:26:32 PM EST
Accepted by the SEC: Tue May 10 2016
Period: Thursday, March 31, 2016
Industry: Electromedical And Electrotherapeutic Apparatus